Henry Schein (HSIC) Reports Q2 Earnings: What Key Metrics Have to Say

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Henry Schein performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- International Distribution and Value-Added Services- Dental: $935 million versus the four-analyst average estimate of $889.96 million. The reported number represents a year-over-year change of +10.9%.
• Geographic Revenue- International Distribution and Value-Added Services- Medical: $30 million versus the four-analyst average estimate of $30.38 million. The reported number represents a year-over-year change of +7.1%.
• Geographic Revenue- U.S. Distribution and Value-Added Services: $1.95 billion compared to the $1.9 billion average estimate based on four analysts. The reported number represents a change of +4.6% year over year.
• Geographic Revenue- U.S. Distribution and Value-Added Services- Dental- Merchandise: $652 million versus the four-analyst average estimate of $613.29 million. The reported number represents a year-over-year change of +8.3%.
• Net Sales- Global Specialty Products: $419 million compared to the $406.78 million average estimate based on five analysts. The reported number represents a change of +8.6% year over year.
• Net Sales- Global Technology: $181 million versus the five-analyst average estimate of $174.78 million. The reported number represents a year-over-year change of +8.4%.
• Net Sales- Global Distribution and Value-Added Services: $2.91 billion versus $2.82 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
• Net Sales- Eliminations: $-53 million versus $-44.68 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +20.5% change.
• Net Sales- Global Distribution and Value-Added Services- Global Dental: $1.85 billion compared to the $1.78 billion average estimate based on four analysts. The reported number represents a change of +8.1% year over year.
• Net Sales- Global Distribution and Value-Added Services- Global Medical: $1.06 billion versus $1.05 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4% change.
• Geographic Revenue- International Distribution and Value-Added Services: $965 million compared to the $920.35 million average estimate based on four analysts. The reported number represents a change of +10.8% year over year.
• Net Sales- Global Distribution and Value-Added Services- Global Dental- Global Equipment: $456 million versus $454.24 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.9% change.

View all Key Company Metrics for Henry Schein here>>>

Shares of Henry Schein have returned -0.1% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research